In the pharmaceutical industry, the departure of senior executives of pharmaceutical companies has long become the norm, and since November this year, there have been many more cases, mostly due to personal reasons
.
On November 22, Shanghai Medixi Biopharmaceutical Co.
, Ltd.
issued an announcement
on the change of commitment of the actual controller and the termination of the concerted action relationship.
After this change of commitment, the "Concerted Action Relationship Termination Agreement" and the new "Concerted Action Agreement" came into effect, and the actual controller of the company was changed from Chen Jinzhang, CHUN-LINCHEN and Chen Jianhuang to Chen Jinzhang and CHUN-LINCHEN, and the total shareholding ratio of the actual controller of the company decreased from 31.
75% to 21.
86%.
THE ANNOUNCEMENT SHOWS THAT CHEN JIANHUANG INTENDS TO WITHDRAW FROM THE ACTUAL CONTROLLER OF THE COMPANY BECAUSE HE DOES NOT ACTUALLY PARTICIPATE IN THE COMPANY'S PRODUCTION AND OPERATION, AND HAS MANY SOCIAL POSITIONS, AND HIS PERSONAL ENERGY IS LIMITED, AND THE ACTUAL CONTROLLER OF THE COMPANY WILL BE CHANGED TO CHEN JINZHANG AND CHUN-LINCHEN.
On November 16, YaoTesco issued an announcement that Hao Ruizhi recently applied to resign as the secretary of the company's board of directors and deputy general manager due to personal reasons
.
Sinovac announced on November 15 that Ms.
Shi Weijin applied to resign as the company's deputy general manager due to personal reasons, and will no longer hold any position
in the company after her resignation.
On November 2, Cylon Pharmaceutical also issued an announcement on the resignation of the company's deputy general manager, and Mr.
Tong Yan, the company's deputy general manager, applied to resign as the company's deputy general manager due to personal reasons.
.
.
In fact, since the beginning of this year, the senior management of pharmaceutical companies has been very frequent, and the wave of departures has also been constantly setting
off.
Incomplete statistics show that as of November 17, more than 1,400 senior executives in the A-share biopharmaceutical industry have left the company, including executives from the Greater China region of multinational pharmaceutical companies, management of traditional pharmaceutical companies, and R&D leaders and founders of biopharmaceutical companies, involving 357 enterprises
.
It is understood that in the same period of 2021, the total number of executives leaving the industry was 1,328, involving 319 companies; In the same period of 2020, 293 companies were involved, and the total number of executives leaving was 1,284
.
In terms of quantity, changes in senior management in the biomedical industry can be said to be becoming more frequent
in recent years.
In this regard, the industry believes that the departure of executives is related to
the current great pressure on the pharmaceutical industry.
At present, the competition of marketing channels and marketing resources in the pharmaceutical industry is intensifying, and the profit margins of some pharmaceutical companies are also continuously squeezed, affected by a variety of factors, pharmaceutical companies have begun to adjust their development strategies and accelerate innovation and transformation, which has also brought more frequent executive changes
.
It is understood that there are 19 companies with more than 10 departures in the A-share biomedical industry this year, and 91 companies with 5-10 departures
.
Among them, the company with a large number of senior departures is Unnamed Pharmaceutical, which has had frequent departures of executives since the beginning of the year, with 21 departures, including 11 directors
.
Recently, the departure of the senior management occurred on August 9, and Wuming Pharmaceutical issued an announcement that its founder and chairman Pan Aihua officially stepped down, and Yue Jialin became the company's chairman
.
Industry analysts believe that in the context of the transformation and upgrading of the existing pharmaceutical industry, while talent standards are being comprehensively adjusted, they are also requiring enterprises to build a new talent system
.
Affected by this, in the future, the management of pharmaceutical companies will accelerate the elimination of some people, and at the same time introduce more talents
with professional capabilities and matching the current development of the company.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
